QGEN QIAGEN N.V.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1015820 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY5.7%
TTM net income YoY408.3%
TTM EPS YoY424.3%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR0.1%
Margins
Gross margin62.2%
Operating margin22.3%
Net margin20.3%
FCF margin21.7%
EBITDA margin31.6%
Returns
ROE11.6%
ROA7.1%
ROIC (approx.)9.1%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets39.9%
Debt / equity0.44x
Current ratio3.90x
Interest coverage14.01x
Cash quality & payout
Operating cash flow / net income1.54x
Accruals ratio-3.8%
Payout ratio12.8%
Capex / revenue9.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Cost of revenue | $790.50M | $1.01B | $731.62M | $756.96M | $800.84M |
| Gross profit | $1.30B | $967.35M | $1.23B | $1.38B | $1.45B |
| R&D expense | $187.52M | $193.49M | $198.51M | $189.86M | $189.96M |
| SG&A expense | $125.68M | $113.43M | $119.25M | $129.72M | $128.08M |
| Operating income | $465.85M | $97.71M | $409.94M | $531.46M | $630.08M |
| Interest expense | $33.26M | $43.84M | $53.41M | $58.36M | $54.48M |
| Pretax income | $490.26M | $121.15M | $429.81M | $512.60M | $625.83M |
| Income tax | $65.39M | $37.56M | $88.51M | $89.39M | $113.23M |
| Net income | $424.88M | $83.59M | $341.30M | $423.21M | $512.60M |
| EBITDA | $659.60M | $300.98M | $615.27M | $739.86M | $845.01M |
| EPS (basic) | 1.96 | 0.38 | 1.50 | 1.86 | 2.25 |
| EPS (diluted) | 1.94 | 0.37 | 1.48 | 1.84 | 2.21 |
| Dividends declared per share | 0.25 | — | — | — | — |
| Weighted avg. shares (diluted) | 218.88M | 224.72M | 230.62M | 230.14M | 232.03M |
| Balance sheet | |||||
| Cash & equivalents | $839.00M | $663.55M | $668.08M | $730.67M | $880.52M |
| Short-term investments | $259.91M | $489.44M | $389.70M | $687.60M | $184.78M |
| Receivables | $402.61M | $349.28M | $381.88M | $323.75M | $362.13M |
| Inventory | $301.89M | $279.26M | $398.38M | $357.96M | $327.52M |
| Current assets | $2.00B | $1.96B | $2.15B | $2.39B | $2.11B |
| PP&E, net | $923.95M | $753.61M | $765.04M | $662.17M | $638.18M |
| Goodwill | $2.70B | $2.43B | $2.48B | $2.35B | $2.35B |
| Intangibles | $386.43M | $303.81M | $526.82M | $544.80M | $627.44M |
| Total assets | $6.28B | $5.69B | $6.12B | $6.29B | $6.15B |
| Current liabilities | $512.14M | $1.04B | $1.08B | $974.52M | $1.52B |
| Short-term debt | $0 | $551.88M | $587.97M | $389.55M | $847.63M |
| Long-term debt | $1.65B | $839.66M | $921.82M | $1.47B | $1.09B |
| Total debt | $1.65B | $1.39B | $1.51B | $1.86B | $1.94B |
| Total liabilities | $2.50B | $2.12B | $2.31B | $2.82B | $3.05B |
| Shareholders' equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.10B |
| Net debt | $815.42M | $727.99M | $841.71M | $1.13B | $1.06B |
| Cash flow statement | |||||
| Operating cash flow | $654.33M | $673.55M | $459.45M | $715.26M | $639.00M |
| Capital expenditure | $201.05M | $167.17M | $149.71M | $129.22M | $189.90M |
| Free cash flow | $453.28M | $506.38M | $309.75M | $586.04M | $449.10M |
| Investing cash flow | -$305.28M | -$249.23M | -$87.66M | -$726.76M | -$202.43M |
| Financing cash flow | -$178.98M | -$422.90M | -$433.83M | -$125.80M | -$150.37M |
| Depreciation & amortization | $193.75M | $203.27M | $205.34M | $208.40M | $214.93M |
| Stock-based compensation | $50.40M | $43.63M | $47.10M | $49.51M | $38.39M |
| Dividends paid | $54.24M | $0 | $0 | — | — |
| Share buybacks | $280.09M | $292.10M | $0 | $0 | $99.99M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.